Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Nat Commun
; 13(1): 5579, 2022 Sep 23.
Article
in En
| MEDLINE
| ID: mdl-36151107
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Diagnostic_studies
Language:
En
Journal:
Nat Commun
Year:
2022
Document type:
Article